Discover 214 paid clinical trials in Montana. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Whether you’re looking to join as a healthy volunteer in a paid clinical trial or need condition-specific options, Montana has a wide range of research opportunities to suit. Active recruitment is underway at research centers in Billings, Missoula, and Great Falls, allowing participants to access advanced treatments and high-quality medical care.
Filter
1
Filter results
Results: 214
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Springfield MA, Saint Johnsbury VT, Lebanon NH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase 2, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Waterford CT, New Haven CT, Stony Brook NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Saint Johnsbury VT, Lebanon NH, Commack NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase 3, Recruiting
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
for
Obesity or Overweight
Location: New York NY, Morehead City NC, Wilmington NC,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07575399
Phase 3, Recruiting
Active & Responsive
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study